PMID- 12409642
OWN - NLM
STAT- MEDLINE
DCOM- 20030226
LR  - 20191106
IS  - 1072-4109 (Print)
IS  - 1072-4109 (Linking)
VI  - 9
IP  - 6
DP  - 2002 Nov
TI  - Testing for HER-2/neu in breast cancer: is fluorescence in situ hybridization 
      superior in predicting outcome?
PG  - 338-44
AB  - Testing for alterations in HER-2/neu in breast cancer has become increasingly 
      popular in recent years, particularly with the recent development of a humanized 
      antiHER-2/neu monoclonal antibody, trastuzumab, which is currently being employed 
      in conjunction with cytotoxic chemotherapy to treat metastatic breast cancer in 
      patients whose tumors exhibit this HER-2/neu alteration. Controversy exists not 
      only on the optimal method of laboratory testing for this HER-2/neu alteration 
      (i.e., fluorescence in situ hybridization (FISH) versus immunohistochemistry 
      (IHC) versus others), but also on the type of reagents used for a given method. A 
      plethora of published studies on tissue-based HER-2/neu testing has recently 
      appeared in many peer-reviewed journals; many have concluded that IHC could be 
      used as a first-line screening test, with the recommendation of FISH to confirm 
      indeterminate results. In contrast to these studies, a recent study by Pauletti 
      et al. showed that HER-2/neu testing by IHC does not predict clinical outcome as 
      accurately as does FISH. This commentary discusses the findings of this study, 
      within a broader review of critical issues relating to HER-2/neu testing in 
      breast cancer.
FAU - Yaziji, Hadi
AU  - Yaziji H
AD  - PhenoPath Laboratories, 551 North 34th Street, Suite 100, Seattle, WA 98103, USA.
FAU - Gown, Allen M
AU  - Gown AM
LA  - eng
PT  - Comment
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Adv Anat Pathol
JT  - Advances in anatomic pathology
JID - 9435676
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
CON - J Clin Oncol. 2000 Nov 1;18(21):3651-64. PMID: 11054438
MH  - Antibodies, Monoclonal
MH  - Antibodies, Monoclonal, Humanized
MH  - Breast Neoplasms/*diagnosis/genetics/mortality
MH  - Female
MH  - Humans
MH  - *Immunoenzyme Techniques
MH  - *In Situ Hybridization, Fluorescence
MH  - Mass Screening
MH  - Pilot Projects
MH  - Prognosis
MH  - *Receptor, ErbB-2/analysis/genetics
MH  - Reproducibility of Results
MH  - Survival Rate
MH  - Trastuzumab
RF  - 22
EDAT- 2002/11/01 04:00
MHDA- 2003/02/27 04:00
CRDT- 2002/11/01 04:00
PHST- 2002/11/01 04:00 [pubmed]
PHST- 2003/02/27 04:00 [medline]
PHST- 2002/11/01 04:00 [entrez]
AID - 10.1097/00125480-200211000-00002 [doi]
PST - ppublish
SO  - Adv Anat Pathol. 2002 Nov;9(6):338-44. doi: 10.1097/00125480-200211000-00002.